{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:44:48Z","timestamp":1792151088729,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tianjin Health Science and Technology Projects","award":["TJWJ2025MS011"],"award-info":[{"award-number":["TJWJ2025MS011"]}]},{"name":"the General Program of Tianjin Natural Science Foundation Joint Fund","award":["Project No. 25JCLMJC00580"],"award-info":[{"award-number":["Project No. 25JCLMJC00580"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82570277\uff0c82600493"],"award-info":[{"award-number":["No. 82570277\uff0c82600493"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor T-cell (CAR-T) therapy targeting the C-type lectin-like molecule-1 (CLL1) antigen has emerged as a promising therapeutic approach for acute myeloid leukemia (AML). However, its clinical translation is hindered by on-target, off-tumor toxicity, particularly severe neutropenia caused by CLL1 expression on normal neutrophils. To address this limitation, we constructed a synthetic Notch (SynNotch) dual-antigen AND-gated CAR-T system targeting CD123 and CLL1 to improve tumor specificity and reduce off-tumor toxicity. CD123 and CLL1 expression was first assessed in AML cell lines and primary AML blasts by flow cytometry. The in vitro cytotoxicity, serial killing activity, cytokine secretion, exhaustion-associated protein markers, and transcriptomic profiles of engineered CAR-T cells were then evaluated, and therapeutic efficacy and safety were further examined in AML xenograft models. SynNotch CD123 and CLL1 CAR-T cells showed stronger cytotoxic activity against AML blasts while exhibiting reduced activity toward normal neutrophils. In addition, these cells displayed lower expression of exhaustion-associated genes and markers, together with increased expression of genes related to naive\/memory differentiation. In vivo, this CAR-T variant showed improved expansion, longer persistence, and stronger anti-leukemic activity, together with less severe neutropenia. Increased cytokine production in vitro indicated stronger T-cell activation but also suggested the need for careful evaluation of potential cytokine-related toxicity. These findings indicate that SynNotch dual-antigen-gated CAR-T cells may provide a more specific and potentially safer therapeutic strategy for relapsed\/refractory AML.<\/jats:p>","DOI":"10.1186\/s43556-026-00598-y","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:47:32Z","timestamp":1792147652000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synthetic Notch CD123 and CLL1 chimeric antigen receptor T-cells (CAR-T) target acute myeloid leukemia and reduce off-tumor effects associated with CLL1 CAR-T cells"],"prefix":"10.1186","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6605-2458","authenticated-orcid":false,"given":"Rui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengnan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"1","key":"598_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","volume":"16","author":"RS Bhansali","year":"2023","unstructured":"Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023;16(1):29. https:\/\/doi.org\/10.1186\/s13045-023-01424-6.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"598_CR2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1001\/jamaoncol.2022.7605","volume":"9","author":"M Bornh\u00e4user","year":"2023","unstructured":"Bornh\u00e4user M, Schliemann C, Schetelig J, R\u00f6llig C, Kramer M, Glass B, et al. Allogeneic hematopoietic cell transplantation vs standard consolidation chemotherapy in patients with intermediate-risk acute myeloid leukemia: a randomized clinical trial. JAMA Oncol. 2023;9(4):519\u201326. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7605.","journal-title":"JAMA Oncol"},{"issue":"1","key":"598_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02841-8","volume":"42","author":"E Peroni","year":"2023","unstructured":"Peroni E, Randi ML, Rosato A, Cagnin S. Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. Dissect cancer heterogeneity and tailor the treatment. J Exp Clin Cancer Res. 2023;42(1):259. https:\/\/doi.org\/10.1186\/s13046-023-02841-8.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"598_CR4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38(4):473\u201388. https:\/\/doi.org\/10.1016\/j.ccell.2020.07.005.","journal-title":"Cancer Cell"},{"issue":"1","key":"598_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-020-0848-x","volume":"3","author":"Z Yang","year":"2020","unstructured":"Yang Z, Yu Z, Cai Y, Du R, Cai L. Engineering of an enhanced synthetic notch receptor by reducing ligand-independent activation. Commun Biol. 2020;3(1):116. https:\/\/doi.org\/10.1038\/s42003-020-0848-x.","journal-title":"Commun Biol"},{"issue":"591","key":"598_CR6","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd8836","volume":"13","author":"A Hyrenius-Wittsten","year":"2021","unstructured":"Hyrenius-Wittsten A, Su Y, Park M, Garcia JM, Alavi J, Perry N, et al. SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci Transl Med. 2021;13(591):eabd8836. https:\/\/doi.org\/10.1126\/scitranslmed.abd8836.","journal-title":"Sci Transl Med"},{"issue":"591","key":"598_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe7378","volume":"13","author":"JH Choe","year":"2021","unstructured":"Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021;13(591):eabe7378. https:\/\/doi.org\/10.1126\/scitranslmed.abe7378.","journal-title":"Sci Transl Med"},{"issue":"1","key":"598_CR8","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41467-020-20785-x","volume":"12","author":"B Moghimi","year":"2021","unstructured":"Moghimi B, Muthugounder S, Jambon S, Tibbetts R, Hung L, Bassiri H, et al. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nat Commun. 2021;12(1):511. https:\/\/doi.org\/10.1038\/s41467-020-20785-x.","journal-title":"Nat Commun"},{"key":"598_CR9","doi-asserted-by":"publisher","unstructured":"Zhang J, Siller-Farf\u00e1n JA. Current and future perspectives of chimeric antigen receptors against glioblastoma. Immunother Adv. 2022;2(1):ltac014. https:\/\/doi.org\/10.1093\/immadv\/ltac014","DOI":"10.1093\/immadv\/ltac014"},{"key":"598_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01448","volume":"9","author":"H Luo","year":"2019","unstructured":"Luo H, Wu X, Sun R, Su J, Wang Y, Dong Y, et al. Target-dependent expression of IL12 by synNotch receptor-engineered NK92 cells increases the antitumor activities of CAR-T cells. Front Oncol. 2019;9:1448. https:\/\/doi.org\/10.3389\/fonc.2019.01448.","journal-title":"Front Oncol"},{"issue":"3","key":"598_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","volume":"35","author":"S Srivastava","year":"2019","unstructured":"Srivastava S, Salter AI, Liggitt D, Yechan-Gunja S, Sarvothama M, Cooper K, et al. Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell. 2019;35(3):489-503.e8. https:\/\/doi.org\/10.1016\/j.ccell.2019.02.003.","journal-title":"Cancer Cell"},{"issue":"12","key":"598_CR12","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1038\/bcj.2016.115","volume":"6","author":"A Nazha","year":"2016","unstructured":"Nazha A, Zarzour A, Al-Issa K, Radivoyevitch T, Carraway HE, Hirsch CM, et al. The complexity of interpreting genomic data in patients with acute myeloid leukemia. Blood Cancer J. 2016;6(12):e510. https:\/\/doi.org\/10.1038\/bcj.2016.115.","journal-title":"Blood Cancer J"},{"issue":"7382","key":"598_CR13","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature10738","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481(7382):506\u201310. https:\/\/doi.org\/10.1038\/nature10738.","journal-title":"Nature"},{"issue":"1","key":"598_CR14","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1038\/s41467-021-26683-0","volume":"12","author":"N El Khawanky","year":"2021","unstructured":"El Khawanky N, Hughes A, Yu W, Myburgh R, Matschulla T, Taromi S, et al. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nat Commun. 2021;12(1):6436. https:\/\/doi.org\/10.1038\/s41467-021-26683-0.","journal-title":"Nat Commun"},{"issue":"1","key":"598_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-017-0553-5","volume":"11","author":"J Wang","year":"2018","unstructured":"Wang J, Chen S, Xiao W, Li W, Wang L, Yang S, et al. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J Hematol Oncol. 2018;11(1):7. https:\/\/doi.org\/10.1186\/s13045-017-0553-5.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"598_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009013","volume":"12","author":"R Freeman","year":"2024","unstructured":"Freeman R, Shahid S, Khan AG, Mathew SC, Souness S, Burns ER, et al. Developing a membrane-proximal CD33-targeting CAR T cell. J Immunother Cancer. 2024;12(5):e009013. https:\/\/doi.org\/10.1136\/jitc-2024-009013.","journal-title":"J Immunother Cancer"},{"issue":"19","key":"598_CR17","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1182\/blood.2020009192","volume":"138","author":"H Jetani","year":"2021","unstructured":"Jetani H, Navarro-Bail\u00f3n A, Maucher M, Frenz S, Verbruggen C, Yeguas A, et al. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. Blood. 2021;138(19):1830\u201342. https:\/\/doi.org\/10.1182\/blood.2020009192.","journal-title":"Blood"},{"issue":"9","key":"598_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000937","volume":"7","author":"J Vanhooren","year":"2023","unstructured":"Vanhooren J, Dobbelaere R, Derpoorter C, Deneweth L, Van Camp L, Uyttebroeck A, et al. CAR-T in the treatment of acute myeloid leukemia: barriers and how to overcome them. HemaSphere. 2023;7(9):e937. https:\/\/doi.org\/10.1097\/HS9.0000000000000937.","journal-title":"HemaSphere"},{"issue":"12","key":"598_CR19","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/s41423-024-01228-9","volume":"21","author":"R Zheng","year":"2024","unstructured":"Zheng R, Shen K, Liang S, Lyu Y, Zhang S, Dong H, et al. Specific ECM degradation potentiates the antitumor activity of CAR-T cells in solid tumors. Cell Mol Immunol. 2024;21(12):1491\u2013504. https:\/\/doi.org\/10.1038\/s41423-024-01228-9.","journal-title":"Cell Mol Immunol"},{"issue":"6625","key":"598_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1624","volume":"378","author":"GM Allen","year":"2022","unstructured":"Allen GM, Frankel NW, Reddy NR, Bhargava HK, Yoshida MA, Stark SR, et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science. 2022;378(6625):eaba1624. https:\/\/doi.org\/10.1126\/science.aba1624.","journal-title":"Science"},{"issue":"1","key":"598_CR21","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1038\/s41467-023-37863-5","volume":"14","author":"E Ruffo","year":"2023","unstructured":"Ruffo E, Butchy AA, Tivon Y, So V, Kvorjak M, Parikh A, et al. Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting. Nat Commun. 2023;14(1):2463. https:\/\/doi.org\/10.1038\/s41467-023-37863-5.","journal-title":"Nat Commun"},{"issue":"1","key":"598_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01308-1","volume":"15","author":"X Jin","year":"2022","unstructured":"Jin X, Zhang M, Sun R, Lyu H, Xiao X, Zhang X, et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia. J Hematol Oncol. 2022;15(1):88. https:\/\/doi.org\/10.1186\/s13045-022-01308-1.","journal-title":"J Hematol Oncol"},{"key":"598_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102225","volume":"52","author":"R Zhang","year":"2025","unstructured":"Zhang R, Zhao Y, Chai X, Wang Y, Zhao M, Guo S, et al. Modified CD15\/CD16-CLL1 inhibitory CAR-T cells for mitigating granulocytopenia toxicities in the treatment of acute myeloid leukemia. Transl Oncol. 2025;52:102225. https:\/\/doi.org\/10.1016\/j.tranon.2024.102225.","journal-title":"Transl Oncol"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00598-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00598-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00598-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:47:33Z","timestamp":1792147653000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00598-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["598"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00598-y","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"25 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were conducted in accordance with institutional guidelines and approved by the Institutional Animal Care and Use Committee (No. 2025-SYDWLL-000096). The clinical study was approved by the Ethics Committee of Tianjin First Central Hospital (2020N212KY). Clinical trial number: ChiCTR2000041054. Written informed consent was obtained from all participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"215"}}